Homrich & Berg’s DexCom DXCM Stock Holding History

Homrich & Berg’s Portfolio DXCM Stock Details DXCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-2,380	Closed	-$220K	–	420
2020 Q4	$220K	Buy	+2,380	New	+$213K	0.01%	366

Other funds holding DXCM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

LPC

Lone Pine Capital Greenwich, Connecticut $12.5B AUM 54.4% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

Homrich & Berg's DXCM Position: Q1 2021 in Review

Homrich & Berg sold out of DexCom (DXCM) in Q1 2021, closing a stake of 2,380 shares — an estimated $220K sold.

Homrich & Berg first reported a position in DXCM in Q4 2020 and held it in 1 quarter. The position peaked at $220K in Q4 2020. 729 funds tracked by Wall St. Rank hold DXCM as of Q1 2021.

Homrich & Berg reported no remaining DexCom position as of Q1 2021 after selling out during the quarter.
Homrich & Berg sold 2,380 DexCom shares in Q1 2021, an estimated $220K.
Homrich & Berg first reported a position in DexCom in Q4 2020 and held it in 1 quarter.
Homrich & Berg's DexCom position peaked at $220K in Q4 2020.
729 funds tracked by Wall St. Rank held DexCom as of Q1 2021.

Based on Homrich & Berg's 13F filing for Q1 2021, filed 17 May 2021.